ArticleJournal of medical virology2026
Serum Histatin Levels in COVID-19: Association With Disease Severity and Immune Status.
Article in Journal of medical virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Histatins are histidine-rich antimicrobial peptides with emerging immunomodulatory properties; however, their systemic behavior across the clinical spectrum of COVID-19 remains unknown. We aimed to characterize serum histatin levels in patients with mild COVID-19 (without pneumonia) and severe COVID-19 (with pneumonia) and to explore factors potentially associated with their variation. Ninety individuals were prospectively enrolled: healthy controls (n = 30), patients with mild COVID-19 (without pneumonia (n = 30), and patients with severe COVID-19 (with pneumonia receiving corticosteroid therapy (n = 30). Serum histatin-1, histatin-3, and histatin-5 concentrations were quantified by ELISA. Group comparisons were performed using Kruskal-Wallis and Mann-Whitney U tests; correlations were assessed using Pearson coefficients. Histatin-1 did not differ among groups (p = 0.161). Both histatin-3 and histatin-5 were significantly reduced in mild COVID-19 compared with controls (p = 0.004 and p = 0.002, respectively). Unexpectedly, patients with severe COVID-19, all of whom were receiving corticosteroids, did not exhibit further histatin reductions; their levels were comparable to controls and significantly higher than the mild group (histatin-3 p = 0.016; histatin-5 p = 0.028). Histatin-3 correlated significantly with ferritin (r = 0.413; p = 0.009), D-dimer (r = 0.369; p = 0.021), and albumin (r = -0.330; p = 0.018). SARS-CoV-2 infection without pneumonia was associated with significantly lower serum histatin-3 and histatin-5 levels. In contrast, histatin levels were preserved in patients with severe COVID-19 and pneumonia who were receiving corticosteroid therapy. Because of the cross-sectional design, this finding should be interpreted as an association rather than evidence of a treatment effect. The observed correlations between histatin-3 and ferritin, D-dimer, and albumin further suggest that histatin-3 may be linked to acute-phase and inflammatory responses during COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.